Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type.
P. R. Lephart, M. A. Bachman, W. LeBar, S. W. McClellan, K. Barron, L. Schroeder, D. W. Newton
This study compares four SARS-CoV-2 NAAT platforms, finding that ID NOW performs worse than others, especially with nasal swabs and in chronically infected patients.
bioRxiv · Jun 4, 2020Microbiology